Relaxin acts as a pregnancy-specific signal in feline species, but specific information about protein structure and binding is essential for the improvement of pregnancy diagnosis in endangered feline species, like the Iberian lynx. To generate a felid-specific relaxin antibody, the DNA and protein sequences of lynx and cat were determined and peptides were chosen for antibody generation. In addition, relaxin and relaxin receptor (RXFP1) mRNA expressions were measured in uteri and ovaries of pregnant domestic cats and lynx placentae. Using real-time PCR and immunohistochemistry, it was established that feline placenta is the main source of relaxin during pregnancy. In other tested tissues, relaxin mRNA expression was weak. The RXFP1 mRNA expression was found mainly in cat uterine tissue and feline placentae. It was assumed that these tissues were main targets for relaxin. In the ovary, relaxin immunostaining was associated with blood vessels, signifying its role in vascularization.
Introduction
Relaxin is a peptide hormone known to be involved in many physiological processes (for review, see Sherwood (2004) ) and is a key player during pregnancy in mammals. The implantation of the early embryo seems to depend on relaxin. For example, in marmoset monkeys, relaxin levels are higher around time of implantation in the conceptive in comparison with the nonconceptive cycle (Einspanier et al. 1999) . Also, the receptor for relaxin (RXFP1) is upregulated in the uteri of the conceptive cycles (Einspanier et al. 2009 ). In human and other species, relaxin mRNA and/or immunoactivity are localized during the luteal phase of the cycle or early pregnancy within the endometrium. It was suggested that locally produced relaxin supports implantation through autocrine/paracrine mechanisms (Sherwood 2004) . Furthermore, relaxin promotes uterine growth and development during pregnancy; these effects are influenced by estrogen, for instance in rat and pig (Sherwood et al. 1993) . Also in marmoset monkeys, exogenous application of relaxin during pregnancy resulted in a significant effect on endometrial thickness (Einspanier et al. 2009 ). There is increasing evidence that relaxin inhibits myometrial contractions induced by either oxytocin or prostaglandin and that relaxin may contribute to cardiovascular adaptations during pregnancy through effects on the kidney, vasculature, and heart (Sherwood 1994 (Sherwood , 2004 . Endogenous relaxin has been demonstrated to promote a dramatic increase in the softening of the cervix in pregnant rats and pigs (Sherwood et al. 1993) .
Relaxin is a member of the relaxin peptide family and is synthesized as a preprohormone with a signal sequence for secretion and the classic B-C-A structure of insulin-like peptides (Sherwood 2004 , Kong et al. 2010 . Only the six cysteine residues responsible for conferring structure are conserved across all the relaxinlike peptides (Wilkinson et al. 2005) . In the mature relaxin, the A and B chains are connected by two disulfide bridges and one more intrachain bond is located on the A chain (Marriott et al. 1992 , Kong et al. 2010 . The known receptors for the relaxin family peptides are G-protein-coupled receptors. Each binds to one preferred ligand, but most of them are also able to bind, with varying affinity, to some other family members (Bathgate et al. 2006 , Kong et al. 2010 . The main receptor for relaxin is RXFP1, although RXFP2 -primary binding INSL3 -can also bind human relaxin (Halls et al. 2007) . Porcine relaxin can bind to RXFP1 and also RXFP2 (Hsu et al. 2002) . Both receptors belong to the LGR (leucine-rich repeat (LRR)-containing guanine nucleotide (G-protein)-coupled receptor) family, which is structurally and functionally different from the other two receptors (RXFP3 and RXFP4). The LGR type C receptors, in which RXFP1 and RXFP2 are the only two members, contain an extracellular domain with a lowdensity lipoprotein module and multiple LRRs (Bathgate et al. 2006) . RXFP1 is widely expressed in reproductive tissue (reviewed in Bathgate et al. (2006) and Kong et al. (2010) ) but is also found, amongst others, in the brain, kidney, muscle, and heart (Hsu et al. 2000 (Hsu et al. , 2002 .
In all mammals examined so far, relaxin plays a role in pregnancy regulation, although the expression profiles and source are species specific. In mice, rats, pigs, and humans, the main source for circulating relaxin was corpora lutea (Sherwood 2004) . In pigs, relaxin levels increased only slightly during the main part of pregnancy; however, some days before term, a surge of relaxin was observed, which is coincident with functional luteolysis (Eldridge-White et al. 1989) . In marmoset monkeys, serum levels increased during the second trimester of pregnancy, synchronizing with the observed shift from ovarian to placental steroidogenesis. The level stayed elevated for 5 weeks and declined through the third trimester of pregnancy. In contrast, human serum relaxin levels peaked in the first half of pregnancy (Eddie et al. 1986 ). After ovariectomy, relaxin was no longer detectable in human molar pregnancies (Seki & Kato 1987) . Based on mRNA expression, relaxin was detected not only in corpus luteum (CL; Ivell et al. 1989 ) but also in human decidua parietalis and cytotrophoblast cells (Sakbun et al. 1990 , Hansell et al. 1991 , Bogic et al. 1995 .
The placenta appeared to be the main source of relaxin in dogs (Steinetz et al. 1989) , although relaxinrelated bioactivity was also detected in the ovary (Steinetz et al. 1990 , Tsutsui & Stewart 1991 . The relaxin hormone profile during the course of pregnancy was characterized by elevated values from the fourth week until the end of the 65-day gestation (Steinetz et al. 1989 , Concannon et al. 2001 .
In cats, the time course during pregnancy was determined by serum and urine. The relaxin levels increased from the beginning of the second trimester reaching a plateau around day 32 and declined in the last 10-15 days of the 65-day pregnancy (Stewart & Stabenfeldt 1985 , de Haas van Dorsser et al. 2006 . Leopards showed a slightly shifted urine relaxin profile with a massive increase after mid-pregnancy (de Haas van Dorsser et al. 2006 , Steinetz et al. 2009 ). Beside relaxin detection by RIA, a benchtop kit (Witness test) was utilized for pregnancy diagnosis in domestic cats and other nondomestic felid species (de Haas van Dorsser et al. 2007 , Harris et al. 2008 . No relaxin signals were found in the urine of pregnant cheetahs, lions, and a sand cat (Harris et al. 2008) ; only in domestic and Pallas' cat urine and serum samples were relaxin signals detected, indicating an ongoing pregnancy (de Haas van Dorsser et al. 2007 , Harris et al. 2008 ).
This benchtop kit was likewise used for the pregnancy diagnosis in the Iberian lynx (Lynx pardinus (L. pardinus)), where relaxin was detected from days 32 to 56 in blood collected by bugs and between days 29 and 46 in concentrated urine (Braun et al. 2009 ). The Witness relaxin test was suggested as a managing tool for the Iberian lynx Conservation Breeding Program in Spain. The Iberian lynx is the world's most endangered wild felid (International Union for Conservation of Nature red list) and the captive breeding program focuses on the conservation of genetic diversity of this critically endangered species and a reintroduction in near future. Owing to high perinatal losses, an intensive birth management was needed; an easy pregnancy diagnosis tool based on urine or fecal samples would be most effective (Finkenwirth et al. 2010) . As relaxin was not detected in either nonpregnant or pseudopregnant lynxes, it was suggested that the placenta, and not the CL, was the main source of relaxin. This was confirmed by a study on the domestic cat, where relaxin immunoreacitvity was detected by RIA mainly in placental tissues and in lower levels in CL, fetus, and uterus (Addiego et al. 1987) . In addition, the cellular localization of placental relaxin was also shown by in situ hybridization and immunohistochemistry (Klonisch et al. 1999a) .
The aim of the study was to improve the relaxin-based pregnancy diagnosis in the Iberian lynx. In order to generate a felid-specific relaxin antibody, the DNA and protein sequences of lynx and cat were determined and compared. Peptides were chosen for antigen production and the specificity of the generated antibody was tested by immunohistochemistry. In addition, relaxin and relaxin receptor mRNA expressions in pregnant domestic cat placenta, uterine, and ovarian samples and expression in lynx placenta were measured.
Results

cDNA sequences of relaxin and RXFP1
The relaxin cDNA sequence (EU177873) of the L. pardinus comprises 732 bp (Fig. 1A) . It contains an open reading frame of 546 bp coding for 181 amino acid relaxin preproprotein (ABX38714). The Felis catus (F. catus) sequence (JN165028) is not only longer (662 bp) than the previously published sequences (AF233688, 543 bp) but also differs in four positions. These substitutions do not change the derived amino acid sequences (JN165028 and AAF60303).
The cat and lynx cDNA relaxin sequences share a similarity of 98% with only eight different base pairs (Fig. 1A) . In addition, an insertion of 3 bp coding for one additional amino acid in the B-peptide (Fig. 1B) was found in the lynx sequence but not in the cat (Fig. 1A) . A comparison with published relaxin sequences revealed that the lynx-coding region expresses similarities of 76% to the porcine (Sus scrofa, A06852), 75% to canine (Canis familiaris, AF233687), 71% to human relaxin 2 transcript variant 1 (NM_134441), or 69% to human relaxin 1 (NM_006911) sequences. When considering protein, the species' differences are more pronounced, with similarities of 60% to dog (AAF60302), 46% to pig (CAA00600), and 48% to both human relaxin types. But the lynx relaxin protein sequence (ABX38714.1) shows high similarity (96%) to the domestic cat (Fig. 1B) . Figure 2 represents the comparison of an analyzed partial RXFP1 sequence (413 bp) for both feline species coding for the N-terminal part of the receptor. Both sequences are very similar (99% on protein and DNA level); they differ in only 2 bp and one amino acid. These partial sequences share similarities of 88% to human (NM_021634), 87% to Equus caballus (E. caballus; XM_001500397), and 82% to Bos taurus (B. taurus; XM_610789) on a DNA level and 89% to human (NP_067647.2), 80% to E. caballus (XP_001500447.1), and 71% to B. taurus (XP_610789.3) on a protein level.
RNA expression of relaxin and RXFP1 in female genital tract during pregnancy Figure 3A represents the time course of RNA expression determined in domestic cat placenta between days 21 and 55 of pregnancy. Placental relaxin mRNA rise at the beginning of the second trimester from around 3000 relative copies per nanogram total RNA before day 24 to values of almost 85 000 on day 29. A further strong increase (up to an additional power) was observed after day 31 peaking around day 42/43 with about 950 000 copies per nanogram total RNA. Toward the end of pregnancy, the mRNA level seems to decrease again as shown for two data points on days 50 and 55 but remained at a higher level than that found before day 24 (Fig. 3A) . The aborted lynx placenta from day 41 contained w700 000 copies per nanogram total RNA. In the placenta from an unknown pregnancy day, 39 000 copies were determined (Fig. 3B) . In contrast to relaxin, RXFP1 mRNA level showed no gross changes but considerable day-to-day variation during the time course of pregnancy (Fig. 3A) . In comparison with relaxin mRNA, the expression level was quite low with a mean value of 250 copies/10 ng total RNA. The RXFP1 mRNA expression within both lynx placentae was around 2200 relative copies/10 ng RNA (Fig. 3C) . Figure 4 represents mRNA expression of relaxin and RXFP1 during pregnancy determined in myometrial (parts of myometrium directly next to placenta), uterine (uterus between gestation chambers), CL, and ovarian tissue obtained from domestic cats. In all the tissues, relaxin mRNA was detected at very low levels (usually !400 relative copies/10 ng RNA) and did not change appreciably throughout the pregnancy (Fig. 4) . In contrast, RXFP1 mRNA expression was found to be higher in the myometrium and the total uterine tissue (on average 3000-4000 relative copies/10 ng) in comparison with the corpora lutea and ovarian tissue, where it was almost undetectable.
Control experiments with non-RT template or water did not result in amplification products. Statistical analysis was not done because of the low sample number.
Immunolocalization of relaxin in L. pardinus and F. catus placentae in comparison to E-cadherin and vimentin
In both species, the anti-relaxin antibody seemed to react with the same cell types of the placenta (Figs 5 and 6). Trophoblast cells of the placental labyrinth reacted as well as giant cells and cells of blood vessels. To control the specificity of relaxin staining, the antibody was preincubated with the peptides used for antibody production ( Fig. 5H ) and the primary antibody was omitted (Fig. 5L) . In both the cases, no immunostaining was detected. In the lynx placenta, the relaxin immunoreactions were more intensive in the section of placental labyrinth that was directed toward the fetus (Fig. 5A ) than that in the middle of the labyrinth (Fig. 5B) ; in the cat placenta, the difference was not so distinct ( Fig. 6A and B) . Outside the placental labyrinth, immunostaining was detected in cells of the junctional and glandular zones (Figs 5C, 6C and D) . The origin and specialization of these cells could not be determined with certainty, but we assume that some of them are also blood vessel cells. In the placental labyrinth of both species, the relaxin blood vessel staining seems to be restricted to fetal vessels, but in the other zones, the stained vessels are probably from maternal origin.
Relaxin-related immunoreactivity was also detected in the myometrium (Fig. 7A) , endometrium ( Fig. 7B ), and ovary ( Fig. 7C and D) . In the endometrium, the staining was restricted to blood vessels, whereas in the myometrium, the muscle cell reacted too. In the ovary, the main staining was located in the blood vessels and parts of the stroma ( Fig. 7C and D) , which we believe is strongly vascularized too. In the CL, only vessels are stained, the weak staining of the luteal cells is presumably unspecific. Control experiments with preimmune serum of anti-relaxin antibody ( Fig. 7E and F) or blocking of the antibody with the immunization peptides ( Fig. 7G and H) as well as experiments without the first antibodies (not shown) resulted in negative or weak unspecific staining. Immunodetection of vimentin and E-cadherin was performed to assist the identification of cell types in the placenta and uterus. As expected, E-cadherin was characteristic for fetal trophoblast cells and maternal glandular cells (Figs 5E-G and 6E-H). The anti-vimentin antibody (Figs 5I-K and 6I-L) reacted with different cells of maternal origin but was also found in fetal endothelium and mesenchyme, as described before by Walter & Schonkypl (2006) .
Discussion
The DNA sequence of relaxin has been determined for the first time in a nondomestic felid species, the Iberian lynx. Uncovering the sequence was the prerequisite for the production of a specific peptide antibody against lynx relaxin, which was applied to detect relaxin in the placenta of domestic cats and lynxes. This strong reaction in different placenta cells in immunohistochemistry of both species indicates the placental origin of relaxin during pregnancy. This was supported by mRNA expression of feline relaxin in cat and lynx placenta, expressing peak levels around days 40-45 with up to nearly 1 million mRNA copies per nanogram total RNA. In contrast to that, expression levels in uterus and ovarian tissue never exceeded 600 mRNA copies per nanogram total RNA. The relaxin receptor 1 was found in the placenta and uterine tissue but was almost absent in the ovary. To study the ligand-receptor interaction, the relaxin receptor 1 DNA sequence was partly determined for the cat and lynx.
Understanding the sequences of both F. catus and L. pardinus relaxins allows a comparison of the relaxin of these species with each other and with other previously known relaxin sequences. Both feline sequences express a high similarity, but the lynx relaxin cDNA sequence has one codon more, affecting the B-peptide region. Also, sequences of other species such as the dog (Klonisch et al. 1999b ) and pig (Haley et al. 1982) were characterized by one or two additional amino acids in the B-peptide region in comparison with cat. The preprohormone relaxin consists of four parts aligned in the following order: signal peptide, B, C, and A chains; B and A chains remained in the functional hormone connected by disulfide bonds. The C chain is cleaved after supporting the correct folding and disulfide bridge formation (Marriott et al. 1992 , Kong et al. 2010 . It is remarkable that three of the seven differences between the lynx and the cat peptide sequences are localized in the potential B-peptide region. Additionally, one of them includes a change in an amino acid within the classical receptor-binding motif Arg-X-A.X-Arg-X-X-Ile (Bathgate et al. 2006) but not in the conserved amino acids of it. Perhaps the sequence differences in the B-peptide are responsible for the species-specific part of receptor-ligand interaction. The lynx sequence has a little higher similarity to the sequences of the other compared species than the feline sequence. The sequence differences of both feline species may also explain the quite high variation within the feline family according to the cross-reaction to available relaxin antibodies of different origin. Although antibodies against canine and/or porcine relaxin are able to recognize domestic cat relaxin (Addiego et al. 1987 , Klonisch et al. 1999a (Harris et al. 2008) , the Witness relaxin test, which is based on a canine antibody, worked well for domestic cats and Pallas cat but failed in others, e.g. cheetahs, lions, and sand cat (Harris et al. 2008) . In the lynx, a 50-fold increase in concentration of urine samples was necessary before a positive reaction in Witness relaxin was found (Braun et al. 2009 ). Our new antibody, which was produced against the lynx sequence, might be more suitable for pregnancy detection in felids, especially in the species where the canine system failed. A pregnancy diagnosis for feline species based on relaxin would be helpful to monitor the mid-pregnancy period, a time frame where, at least in the Iberian lynx, a high incidence of abortion was observed. The recently developed pregnancy prostaglandin F2 alpha metabolite (PGFM) test allows a reliable pregnancy diagnosis only within the last trimester (Finkenwirth et al. 2010) .
Our antibody developed against lynx relaxin reacted with different cells of lynx and domestic placenta tissue. We found relaxin signals not only in the same cellstrophoblast cells of the placental labyrinth -as described previously by Klonisch et al. (1999a) but also in trophoblast cells of villous tips, extravillous trophoblast cells of placental junctional zone, giant cells, blood vessel cells, and cells that could not be further specified.
Immunoreactive relaxin was present in cells of both fetal and maternal origin and was not restricted to one specific compartment of the placenta in our study. The origin of these placental cells was verified by immunoreactions against vimentin, which expresses specificity toward fetal mesenchyme cells, maternal endothelial cells, giant cells, and other maternal cells (as described here and by Walter & Schonkypl (2006) ) and against E-cadherin, which detects epithelial cell. Klonisch et al. (1999a) confirmed their immunostaining by in situ hybridization experiments, indicating that the source of relaxin was within the placenta. In some other species, the localization of relaxin was also analyzed in placental tissue. In hamster tissue, the majority of relaxin immunoreactivity was localized within giant trophoblast cells, but there were also signals in endometrial granulocytes of the wall of sheathed arteries (Renegar et al. 1987) . Syncytiotrophoblast cells but no other uteroplacental cells were identified as relaxin-expressing cells by in situ hybridization and immunohistochemistry in dog placenta (Klonisch et al. 1999b ).
We detected relaxin signals in more cat placenta cell types than Klonisch et al. (1999a) . So we suggest that our more specific antibody (with an assumed higher affinity to feline relaxin) was also able to detect relaxin at target cells. Our antibody was generated against parts of both B-and A-peptides. This increased the probability that bound relaxin can also be detected. The presence of relaxin signals in uterine tissue in conjunction with relaxin receptor signals (mRNA expression) may reflect its biological actions via endocrine or paracrine pathways. The myometrium is known as one main target of relaxin during pregnancy. In pigs and rats, it responds to relaxin by inhibition of contractions (Sherwood 1994) . Beside localization in placenta and myometrial cells, we also detected relaxin-positive signals in blood vessel cells in all reproductive tissues analyzed, even in the ovarian cortex and within corpora lutea. Goldsmith et al. (2004) have shown that relaxin stimulates new blood vessel formation in the endometrium in rhesus monkey, Figure 7 Immunohistochemical localization of relaxin in F. catus myometrium (A), endometrium (B; both day 39), ovary (C), and CL (D) (both from day 33). Control stainings: with preimmune serum (E and F) and anti-relaxin antibody pretreated with peptides used for antibody production (G and H) . We detected signals of relaxin in muscle cell (m) of the myometrium, blood vessels (arrows), and stromal cell(s). CL, corpus luteum. Bar(A, B, E, and F)Z50 mm and (C, D, G, and H)Z40 mm. and another study by Shirota et al. (2005) describes how relaxin may contribute to follicle development through the mechanism of angiogenesis in the ovary. There are also special reviews that describe vascular functions of relaxin (Jeyabalan et al. 2007 , Bani 2008 . Thus, our data also support the idea that relaxin influences vascularization.
In pregnant cats, relaxin follows a specific expression profile with highest levels during the second trimester (Stewart & Stabenfeldt 1985 , de Haas van Dorsser et al. 2006 . Interestingly, the mRNA expression in feline placenta shows nearly the same profile. The difference in mRNA expression level comprises two orders of magnitude during the investigated period (days 21-55 of pregnancy). These changes are more distinct than those expected from the circulating blood levels. They elevate by a factor of w10 from 0.5-1 ng/ml on day 20 to 2-4 ng/ml on day 30 and to peak levels of 6-7 ng/ml on days 42-49 (de Haas van Dorsser et al. 2006) .
The expression of the feline relaxin receptor 1 (RXFP1) within the placenta and supposed target tissue (myometrium) did not change over time, although the values in myometrial and uterine tissue were on average higher than the placenta values. In mice, Rxfp1 was predominantly expressed in the myometrium compared with endometrium or placenta of pregnant mice, with a downregulation at term (Parry & Vodstrcil 2007) . In rats, RXFP1 was expressed in the myometrium from early to mid-gestation at levels similar to those determined in nonpregnant rat myometrium, followed by a significant reduction during late gestation. This downregulation in myometrial RXFP1 expression at the end of gestation is indicative of a functional withdrawal of relaxin and may represent a novel mechanism for the activation of spontaneous uterine contractions at labor (Vodstrcil et al. 2010) . As our study did not include late pregnancy, decreasing levels of RXFP1 could not be shown for cats. Before the relaxin-relaxin receptor interplay during feline pregnancies can be finally described, the other relaxin receptor, RXFP2, has to be investigated. In addition to RXFP1, RXFP2 was detected in human uterus (Hsu et al. 2003) , and although INSL3 was determined as the main ligand of RXFP2 (Kumagai et al. 2002) , interaction with H1 relaxin and H2 relaxin in cell culture was shown (Halls et al. 2007) . In ovary and CL tissue, RXFP1 was expressed on a very low level in this study, which suggests that they are not target tissues for relaxin effects mediated by RXFP1 in cats.
Although we had only two lynx placentae, the information was valuable and concurred with most of the data recorded from cat samples. The time course on relaxin in the lynx was determined by Witness relaxin assay (Braun et al. 2009 ) and coincides with feline relaxin profile on mRNA, as described in this publication, serum (Stewart & Stabenfeldt 1985) , and urine levels (de Haas van Dorsser et al. 2006) . We also found immunoreactive relaxin signals in the same placenta cells as for the domestic cat, indicating identical cellular functional relationships. Furthermore, lynx placenta seems to be the main source of relaxin, as we detected levels of lynx relaxin mRNA as high as those found in the domestic cat. The levels of the aborted placenta from day 41 were in the same range as in F. catus samples at the related pregnancy stage.
In summary, we can confirm that the cat placenta is the main source of relaxin during pregnancy and that this can also be assumed for lynx placenta, based on realtime quantitative PCR and immunohistochemical analyses. In the other tissues tested, the relaxin mRNA expression was weak. As we detected RXFP1 mRNA in cat placenta, myometrium, and uterus, as well as in lynx placenta, we can assume that these tissues are target tissues for relaxin mediated by RXFP1. In the ovary, relaxin may be related to vascularization, confirmed by immunostaining of blood vessels, but RXFP1 expression was on a much lower level than in the pregnant uterus.
Future work should focus on the development of a feline-specific relaxin test based on the lynx relaxin antibody and the role of RXFP2 during pregnancy.
Materials and Methods
Tissue collection
Placentae from domestic cats were obtained from the animal shelter, Berlin and other local animal clinics after ovariohysterectomy. The tissue was stored at 4 8C and carried to the laboratory. The day of pregnancy was determined according to the crown-rumps length of the fetus according to Schnorr & Kressin (2006) . For sequence and RNA expression analysis, the placenta was removed from the myometrium and was stored at K80 8C for subsequent RNA isolation. For immunohistochemistry, tissue (placenta connected to myometrium) was fixed in Bouins solution, following the procedure described in the section on Preparation of tissues for immunohistochemistry and detection of relaxin.
L. pardinus placentae were obtained from Spain (El Acebuche Iberian Lynx Captive Breeding Center, Doñ ana). One placenta was collected after an abort on day 41 of pregnancy (determined by day after mating). The second placenta was collected from a lynx killed in a car accident; the day of pregnancy was unknown. Both materials were frozen as soon as possible and stored at K20 8C and K80 8C, and parts of the tissue were also preserved in RNA Stabilization Reagent (Qiagen). Fixation for immunohistochemistry was done with previously frozen tissue in Berlin because fixation could not be done locally in Spain.
Sequence analysis
L. pardinus relaxin
Total RNA for lynx relaxin sequence analysis was isolated with RNeasy Midi Kit (Qiagen) according to the manufacturer's instructions. RNA was finally eluted in 200 ml RNase-free water and its concentration and purity were assessed with the Nanodrop 1000 (Peqlab, Erlangen, Germany). The mRNA was isolated from this total RNA with Oligotex Kit (Qiagen) and further concentrated with RNA Cleanup Kit (Qiagen). This mRNA was used for synthesis of double-stranded cDNA according to a protocol of the CloneMiner cDNA Library Construction Kit of Invitrogen using the following chemicals: Superscript double-stranded cDNA synthesis kit, phenol: chloroform:isoamly alcohol, BP clonase enzyme (all from Invitrogen), T 4 -ligase, glycogen (both from Roche), and nucleotides (BioTez, Berlin, Germany). Briefly, a biotin-attB2-containing Oligo-dT-Primer was used for the first-strand synthesis, and after second-strand synthesis, an adapter (attB1) was ligated to the 5 0 -end. This double-stranded cDNA (a volume corresponding to 3 ng mRNA) was used as a template for PCR reactions amplifying two overlapping parts of the lynx relaxin sequence. Each of these PCR reactions was done with one nonspecific primer and one feline sequencespecific primer (primer combinations: s-attB1-adapter/fRel-rv fRel-fw/Bio-attB2-dT-primer, respectively, see Table 1 , each 750 nM) using 2 U Fast Start Taq polymerase (Roche) in a 50 ml reaction volume (buffer: 50 mM Tris/HCl, 10 mM KCl, 5 mM(NH 4 ) 2 SO 4 , and 2 mM MgCl 2 ; PCR conditions: 2 min denaturation, 30 cycles of 30 s/94 8C, 30 s/57 8C, 45 s/72 8C, and 7 min final elongation at 72 8C). PCR products were purified and sequenced. Based on the information of these sequences, two sequence-specific primers were constructed (lyRel-fw1 and lyRel-rv1, see Table 1 ). They (each 1 mM) and a template (single-stranded cDNA (ss cDNA), synthesized with SuperScript II Reverse Transcriptase (Invitrogen) according to the manufacturer's protocol), corresponding to 120 ng total RNA, were applied in a PCR reaction using 1.25 U High Fidelity Plus polymerase (Roche) in a 25 ml reaction volume (1! Expand HiFi PLUS Reaction Buffer with 1.5 mM MgCl 2 , 200 mM nucleotides, and 1 mM primer; PCR conditions: 2 min denaturation at 94 8C, 30 cycles of 45 s/94 8C, 45 s/52 8C, 90 s/ 72 8C, and 7 min final elongation at 72 8C) to amplify the whole lynx relaxin gene and to confirm -after ligation, cloning, and sequencing -cloning and sequencing of the initial cDNA. For cloning, 10 ng purified PCR products were ligated in 25 ng pGEM-T Easy Vector using 1.5 Weiss units T 4 DNA ligase in 5 ml reaction volume in 1! buffer (1! Rapid Ligation Buffer); 2 ml of each reaction were transformed in 50 ml competent JM109 cells according to the manufacturer's protocol (Promega) and then sequenced by the Services in Molecular Biology GmbH (Dr M Meixner, Humboldt University Berlin).
F. catus relaxin
For F. catus sequence analysis, RNA was isolated from cat placenta (day 55 of pregnancy) with Precellys Tissue RNA Kit (Peqlab) and was transcribed to ss cDNA with cDNA Synthesis Kit containing RevertAidTm M-MuLV RT according to the manufacturer's instructions (Fermentas-Thermo Scientific, St. Leon-Rot, Germany). PCR reaction was carried out with lyRel-fw1 and lyRel-rv1 primer and Expand High Fidelity Plus polymerase (Roche) as described for lynx relaxin. The amplification product was ligated, transformed, and sequenced as described above for lynx relaxin product.
F. catus RXFP1 (partial)
RNA isolation and cDNA transcription was carried out as described above for F. catus relaxin, but myometrial tissue from pregnancy day 39 was used. Primers (RXFP1-fw1 and RXFP1-rv1) were deduced from sequences of other species (see Table 1 ). In the PCR reaction, ss cDNA, transcribed with cDNA Synthesis Kit containing RevertAidTm M-MuLV RT according to the manufacturer's instructions (Fermentas-Thermo Scientific) and corresponding to 100 ng total RNA, was used as template with 1.25 U Expand High Fidelity Plus polymerase (Roche) in a 50 ml reaction volume (1! Expand HiFi PLUS Reaction Buffer with 1.5 mM MgCl 2 , 200 mM nucleotides, and 1 mM primer; PCR conditions: 2 min denaturation at 94 8C, 10 cycles of 60 s/94 8C, 60 s/56-53 8C, 80 s/72 8C, 20 cycles of 60 s/94 8C, 60 s/53 8C, 80 s/72 8C, and 7 min final elongation at 72 8C). The PCR product was ligated, transformed, and sequenced as described above for lynx relaxin product.
L. pardinus RXFP1 (partial)
For analyzing the L. pardinus RXFP1 sequence, ss cDNA, transcribed as described for F. catus relaxin, was used as a template. PCR conditions were the same as for F. catus RXFP1 except for the following modifications: cDNA corresponding to 125 ng total RNA, RXFP1-fw1, and RXFP1-rv1 as primers (each 500 nM), 2.5 mM MgCl 2 , PCR program: 2 min denaturation at 94 8C, 35 cycles of 30 s/94 8C, 30 s/53 8C, 30 s/72 8C, and 7 min final elongation at 72 8C. In contrast to the feline RXFP1 PCR product, the lynx PCR product was ligated to pJET 1.2 (Fermentas-Thermo Scientific) according to their protocol. The 5 ml ligation was transformed in competent JM109 cells; positive clones were analyzed by sequencing.
Expression studies
For expression studies, about 20 mg placental tissue or myometrial tissue from three gestational chambers (day 55 only two) per pregnancy were placed in tubes with 100 ml RNA lysis buffer T-P with 1. (Peqlab) . RNA (DNase I treated) was eluted in 50 ml RNase-free water and its concentration and purity were assessed with the Nanodrop 1000 (Peqlab). One to five micrograms were transcribed in a 40 ml reaction cDNA using cDNA Synthesis Kit containing RevertAidTm M-MuLV RT according to their protocol (Fermentas-Thermo Scientific). For quantitative relaxin, cDNA amplification primers felyRel-qPCR-fw and felyRel-qPCR-rv were used to obtain a 195 bp relaxin fragment and primers fRXFP1-q-fw1 and fRXFP1-q-rv1 to obtain a 151 bp fragment. Further primer information is listed in Table 1 . For normalization, fragments of the reference genes b-actin (b-act, AB051104), b-2-microglobulin (B2MG, NM_001009876), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH, NM_001009307) as already described in Hachen et al. (2011) were amplified. For the qPCR reaction, cDNA was diluted with H 2 O and 4 ml diluted cDNA samples each equivalent to 4 ng total RNA (qPCR reactions with cat placenta cDNA for b-act, B2MG, GAPDH, and relaxin), 8 ng RNA (qPCR reactions with lynx placenta and cat uterine and ovary cDNA for b-act, B2MG, and GAPDH) and 10 ng RNA (qPCR reactions with lynx placenta and cat uterine and ovary cDNA for relaxin and RXFP1, as well as with cat placenta cDNA for RXFP1) were analyzed in a 10 ml reaction volume with the CFX 96 thermocycler (Bio-Rad Laboratories) using SsoFast EvaGreen Supermix (Bio-Rad) and 500 nM of reverse and forward primer each. All qPCR reactions were run in duplicates with a nontemplate-control to check for contaminations. The qPCR conditions were 2 min at 98 8C and 40 cycles of denaturation (98 8C for 8 s) and annealing/elongation (8 s, see temperature for relaxin and RXFP1 in Table 1 , b-act: 62.5 8C, B2MG/ GAPDH: 63.5 8C). Melting curve analysis was performed from 65 8C to 95 8C in 0.5 8C steps each lasting 5 s to confirm the presence of a single product and absence of primer dimers. Calibration points from 10 6 molecules down to 100 molecules per reaction were used as calibration curve for qPCR. For normalization, reference gene results were validated in the qbasePLUS program (Biogazelle, Zwijnaarde, Belgium; Vandesompele et al. 2002) and a normalization factor (NF) was calculated for individual samples. For quantification, target gene real-time PCR quantities from samples were divided by the corresponding NF and corrected by interrun calibration. Afterward, values of samples of one pregnancy day were averaged and the S.D. was calculated.
Polyclonal antiserum production
Custom-made peptide antibody against relaxin was produced by Sigma-Aldrich Chemie GmbH) in New Zealand White Rabbits according to their protocol. Two lynx relaxin peptides were synthesized for immunization: lyRelpA corresponding to a part of the potential A-peptide with a substitution of the internal cysteine to serine (CNVGSTRKELANL) and lyRelpB2 corresponding to a part of the potential B-peptide, also with a substitution of the internal cysteine to serine and an additional cysteine at the N-terminus (CEVLKASGREYVRLQ). For immunization, both peptides were coupled with keyhole limpet hemocyanin by N-(g-maleimidobutyryloxy) succinimide cross-linker. For experiments, we used the final bleeding and the preimmune serum purified with Melon Gel IgG Spin Purification Kit (Thermo Fisher Scientific, Bonn, Germany).
Preparation of tissues for immunohistochemistry and detection of relaxin
For immunohistochemical studies, parts of placenta connected to uterus tissue (lynx placenta: no uterus tissue) were dissected and fixed in Bouins solution for at least 24 h, followed by paraffin embedding. Sections of 3 mm thickness were prepared and placed on microscope slides (Superfrost Plus, Thermo Scientific, Braunschweig, Germany). Sections were deparaffinized in Roti Histol (Carl Roth GmbH, Karlsruhe, Germany) and rehydrated in decreasing concentrations of ethanol before rinsing in PBS (pH 7.2). The antigenic sites were enhanced by incubation of sections in boiling citrate buffer (11 mM, pH 6.0) for 15 min. Then, endogenous peroxidase activity was blocked by incubating the sections for 10 min in 3% H 2 O 2 in methanol followed by blocking with 5% BSA in PBS for 1 h at 37 8C to reduce nonspecific binding of the first antibody. Sections were then incubated overnight with 1:1000 diluted polyclonal rabbit anti-relaxin antibody (see section on Polyclonal antiserum production), 1:50 diluted mouse anti-E-cadherin antibody (Zymed-Invitrogen, Darmstadt, Germany), or 1:100 diluted mouse anti-vimentin antibody (Dako, Hamburg, Germany) at 4 8C. After labeling with primary antibody, sections were washed with PBS-Tween 0.1% and incubated with either peroxidase-conjugated antirabbit or antimouse EnVisionC reagent (Dako, ready for use solution) for 1 h at room temperature. The immunoperoxidase color reaction was developed with diaminobenzidine substrate chromogen solution (Dako). The sections were counterstained with hematoxylin, dehydrated in increasing concentrations of ethanol, and covered with mounting medium and coverslips. The sections were analyzed using an Axioplan microscope, a ProgRes C10 plus camera (both of Carl Zeiss MicroImaging GmbH, Gö ttingen, Deutschland), and a Cell^P Soft Imaging Software (Olympus Soft Imaging Solutions GmbH, Mü nster, Germany). To assess the specificity of the immunolabeling, control experiments were performed by incubating the sections with preimmune serum instead of primary antibody or with the primary antibody pretreated with peptides used for antibody production (see above) or without the first antibody. All other steps and conditions remained the same.
Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.
Funding
This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.
